Trial
NCT00450983
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Fred Hutchinson Cancer Center
Collaborators
National Cancer Institute (NCI); National Institute of Allergy and Infectious Diseases (NIAID)
Condition
Graft Versus Host Disease
Intervention
muromonab-CD3
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-05-24